Terms: = Bone cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
51 results:
1. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
2. Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy.
Nakano K
Jpn J Clin Oncol; 2023 Oct; 53(10):885-892. PubMed ID: 37394916
[TBL] [Abstract] [Full Text] [Related]
3. ret-MAP: An International Multicenter Study on Clinicobiologic Features and treatment Response in Patients With Lung cancer Harboring a ret Fusion.
Aldea M; Marinello A; Duruisseaux M; Zrafi W; Conci N; Massa G; Metro G; Monnet I; Gomez Iranzo P; Tabbo F; Bria E; Guisier F; Vasseur D; Lindsay CR; Ponce-Aix S; Cousin S; Citarella F; Fallet V; Minatta JN; Eisert A; de Saint Basile H; Audigier-Valette C; Mezquita L; Calles A; Mountzios G; Tagliamento M; Remon Masip J; Raimbourg J; Terrisse S; Russo A; Cortinovis D; Rochigneux P; Pinato DJ; Cortellini A; Leonce C; Gazzah A; Ghigna MR; Ferrara R; Dall'Olio FG; Passiglia F; Ludovini V; Barlesi F; Felip E; Planchard D; Besse B
J Thorac Oncol; 2023 May; 18(5):576-586. PubMed ID: 36646211
[TBL] [Abstract] [Full Text] [Related]
4. Receptor Tyrosine Kinase Inhibitors for the treatment of Recurrent and Unresectable bone Sarcomas.
Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
[TBL] [Abstract] [Full Text] [Related]
5. A comparative study of the clinical characteristics of patients with medication-related osteonecrosis of the jaw and osteoporosis or malignancy.
Feng Z; An J; He Y; Zhang Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Nov; 134(5):543-547. PubMed ID: 35668004
[TBL] [Abstract] [Full Text] [Related]
6. Novel Therapeutics and treatment Strategies for Medullary Thyroid cancer.
Walgama E; Busaidy N; Zafereo M
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):379-389. PubMed ID: 35662447
[TBL] [Abstract] [Full Text] [Related]
7. Role of Hemoglobin Content of reticulocyte to Evaluate Anemia in Patients with Malignancy.
Singh G; Chaudhry S; Kumawat A; Kumar G; Singh R
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443540
[TBL] [Abstract] [Full Text] [Related]
8. Extension of Prophylactic Surgery in Medullary Thyroid Carcinoma. Differences Between Sporadic and Hereditary Tumours According to Calcitonin Levels and Lymph Node Involvement.
Juez LD; Mercader E; Amunategui I; Febrero B; Rodríguez JM; Gómez-Ramírez J;
World J Surg; 2022 Apr; 46(4):820-828. PubMed ID: 35089388
[TBL] [Abstract] [Full Text] [Related]
9. Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer.
Matrone A; Prete A; Nervo A; Ragni A; Agate L; Molinaro E; Giani C; Valerio L; Minaldi E; Piovesan A; Elisei R
J Endocrinol Invest; 2021 Oct; 44(10):2139-2151. PubMed ID: 33594641
[TBL] [Abstract] [Full Text] [Related]
10. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
11. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Apolo AB; Nadal R; Tomita Y; Davarpanah NN; Cordes LM; Steinberg SM; Cao L; Parnes HL; Costello R; Merino MJ; Folio LR; Lindenberg L; Raffeld M; Lin J; Lee MJ; Lee S; Alarcon SV; Yuno A; Dawson NA; Allette K; Roy A; De Silva D; Lee MM; Sissung TM; Figg WD; Agarwal PK; Wright JJ; Ning YM; Gulley JL; Dahut WL; Bottaro DP; Trepel JB
Lancet Oncol; 2020 Aug; 21(8):1099-1109. PubMed ID: 32645282
[TBL] [Abstract] [Full Text] [Related]
12. A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast cancer with bone Metastases.
Xu J; Higgins MJ; Tolaney SM; Come SE; Smith MR; Fornier M; Mahmood U; Baselga J; Yeap BY; Chabner BA; Isakoff SJ
Oncologist; 2020 Aug; 25(8):652-660. PubMed ID: 32463152
[TBL] [Abstract] [Full Text] [Related]
13. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with ret Amplification, High Tumor Mutational Burden, and PD-L1 Expression.
Yang X; Shi J; Chen X; Jiang Y; Zhao H
Oncologist; 2020 Jun; 25(6):470-474. PubMed ID: 32100934
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathologic Characteristics, treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract] [Full Text] [Related]
16. Salutary Response to Targeted Therapy in Anaplastic Thyroid cancer.
Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
[No Abstract] [Full Text] [Related]
17. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.
Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD
Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103
[TBL] [Abstract] [Full Text] [Related]
18. LncRNA MALAT1 Promotes cancer Metastasis in Osteosarcoma via Activation of the PI3K-Akt Signaling Pathway.
Chen Y; Huang W; Sun W; Zheng B; Wang C; Luo Z; Wang J; Yan W
Cell Physiol Biochem; 2018; 51(3):1313-1326. PubMed ID: 30481748
[TBL] [Abstract] [Full Text] [Related]
19. Hyaluronic acid-CD44 interactions promote BMP4/7-dependent Id1/3 expression in melanoma cells.
Wu RL; Sedlmeier G; Kyjacova L; Schmaus A; Philipp J; Thiele W; Garvalov BK; Sleeman JP
Sci Rep; 2018 Oct; 8(1):14913. PubMed ID: 30297743
[TBL] [Abstract] [Full Text] [Related]
20. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, ret, and VEGFR2.
Grüllich C
Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760
[TBL] [Abstract] [Full Text] [Related]
[Next]
